Advicenne’s Sibnayal wins reimbursement approval in Spain for distal renal tubular acidosis treatment

Reuters2026/07/20 16:01

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Advicenne’s Sibnayal secured reimbursement in Spain for distal renal tubular acidosis, shifting from early-access supply to funded market access.
Reimbursement prices set at EUR 409.84 for the 24 mEq strength, EUR 136.62 for the 8 mEq strength.
Spanish distribution handled by SPA Farma Iberica, supporting broader patient access in a major European market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advicenne SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260720330336) on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Advicenne’s Sibnayal wins reimbursement approval in Spain for distal renal tubular acidosis treatment

You may also like

Crypto prices